Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
Condition(s):Breast CancerLast Updated:July 18, 2022Withdrawn
Hide Studies Not Open or Pending
Condition(s):Breast CancerLast Updated:July 18, 2022Withdrawn
Condition(s):Scleroderma; Systemic SclerosisLast Updated:August 11, 2016Withdrawn
Condition(s):Recurrent Malignant GliomasLast Updated:July 16, 2010Terminated
Condition(s):Thymoma; Thymic CarcinomaLast Updated:September 30, 2015Completed
Condition(s):Ovarian Cancer; Fallopian Tube Cancer; Peritoneal CancerLast Updated:September 10, 2018Terminated
Condition(s):Hodgkin’s LymphomaLast Updated:January 16, 2014Completed
Condition(s):SarcomaLast Updated:December 29, 2023Recruiting
Condition(s):Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell LymphomaLast Updated:February 15, 2016Terminated
Condition(s):Chronic Infection; HIVLast Updated:July 28, 2020Completed
Condition(s):Hepatocellular CarcinomaLast Updated:December 14, 2020Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.